复旦张江药品价格下调,预计里葆多销售收入将腰斩

DoNews
30 Apr

4月30日,复旦张江公告显示,因盐酸多柔比星脂质体注射液(里葆多)未中选国家集采目录,公司将自5月1日起调整其零售价,降幅不低于35%。受价格调整和销量下滑影响,预计里葆多2025年销售收入同比下降超50%,或面临单产品亏损风险。此次调整执行期至2027年底。免责声明:本文内容由开放的智能模型自动生成,仅供参考。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10